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Summary Several new complexes of platinum with positively charged cellular dyes have been synthesised in
an effort to find chemotherapeutic drugs with increased antitumour cytotoxicity. As part of this effort, the
direct cytotoxicities of some of these complexes as well as their ability to inhibit bleomycin potentially lethal
damage repair (PLDR) was studied in vitro in a squamous cancer cell line of human origin (SCC-25). All of
the new agents were more cytotoxic against exponentially growing than against plateau phase cell cultures.
Exposure of cells to non-lethal drug concentrations for between 1 and 6h led to measurable inhibition of
bleomycin PLDR in the case of each drug tested. In order of decreasing ability to inhibit bleomycin PLDR,
Pt(fast black)2, Pt(thioflavin)2 and Pt(thionin)2 were more effective than CDDP, while Pt(methylene blue)2,
Pt(Rh-123)2 and Pt(pyronin y)2 were less effective. The most directly cytotoxic agents were Pt(thioflavin)2,
Pt(pyronin Y)2 and Pt(Rh-123)2 which also proved to be the least selectively toxic drugs towards exponential
versus plateau phase cells. These results indicate that several of the new platinum complexes may be effective
cytotoxic agents as well as effective inhibitors of DNA repair process following exposure of cells to other
DNA interactive modalities.
The glycopeptide antibiotic bleomycin has demonstrated
clinical usefulness in the treatment of squamous cell cancer
of the head and neck (SCCHN) (Turrisi et al., 1978),
testicular tumours (Einhorn & Donahue, 1977) and lympho-
mas (Coltman et al., 1978). It is used in combinations with
other agents because bleomycin does not exhibit dose limit-
ing haematopoietic toxicity (Hubbard et al., 1975). When
used as a single agent, however, complete response rates are
relatively low and the emergence of drug resistance is a
common problem (Crooke & Bradner, 1976).
To various extents, mammalian tumour cells have the
capacity to repair drug- and radiation-induced damage. The
ability of cells to recover from potentially lethal damage has
been modelled in vitro by maintaining cells in conditions
which prevent them from proliferating for various times and
thereby allowing time for repair processes to take place
(Barranco & Townsend, 1986).
Solid tumours and slow growing lymphomas are likely to
contain large populations of non-cycling cells, which may
have the capacity to repair potentially lethal damage and
contribute to regrowth of the tumour. An in vitro system
containing cells in stationary phase may be more analogous
to the in vivo situation than are cells in exponential growth.
Such an experimental model can be created by growing
monolayer cell cultures to confluency under conditions of
constant medium renewal without subculture. These station-
ary phase cultures contain a large fraction of non-cycling,
but potentially clonogenic, cells (Hahn & Little, 1972). In
such model systems, time dependent enhancement of cell
survival observed with longer pre-subculture intervals follow-
ing exposure to cytotoxic agents can be inferred as due to
potentially lethal damage repair (PLDR) (Ray et al., 1973;
Weichselbaum, 1982).
We have employed a human squamous cell carcinoma cell
line (SCC-25) to study PDLR following bleomycin treatment
and have examined the cytotoxicity of several new platinum-
containing drugs towards exponentially growing and station-
ary phase SCC-25 cells, as well as the ability of the new
agents to inhibit bleomycin PLDR as compared with CDDP.
The effect of these drugs on PLDR following bleomycin
treatment is of particular interest, since combinations of
bleomycin and CDDP have shown enhanced efficacy in the
treatment of SCCHN and testicular tumours (Glick et al.,
1980; Hong et al., 1980; Wittes et al., 1979; Einhorn &
Donohue, 1977).
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Materials and methods
Materials
Bleomycin (Blenoxane') was obtained as a gift from Bristol
Laboratories, Syracuse, NY. Cis-diamminedichloro-
platinum(II) (CDDP) was obtained as pure powder as a gift
from Drs Donald H. Picker and Michael J. Abrams,
Johnson-Matthey Inc., West Chester, PA. The other plati-
num complexes: (rhodamine-l23)2(PtCl4), Pt(Rh-123)2; (fast
black)2PtCl4, Pt(fast black)2; (pyronin Y)2PtCl4, Pt(pyronin
Y)2; (thioflavin)2PtCl4, Pt(thioflavin)2; (thionin)2PtCl4,
Pt(thionin)2; and (methylene blue)2PtCl4, Pt(methylene
blue)2 were prepared in our laboratory by previously des-
cribed methods (Teicher et al., 1986; Abrams et al., 1986)
(see Figure 1).
Cell line
The SCC-25 cell line was derived from the biopsy of a
human squamous cell carcinoma of the tongue and was
established and characterised initially by J.G. Rheinwald at
the Dana-Farber Cancer Institute (Rheinwald & Beckett,
1981). Monolayers were maintained in Dulbecco's minimum
essential medium (DMEM) supplemented with 5% fetal
bovine serum, hydrocortisone (0.4,ugml-1) and antibiotics
(Frei et al., 1985; Teicher et al., 1986). This cell line had a
plating efficiency of 22+7% and a doubling time of 48h
(Frei et al., 1985).
Survival studies
SCC-25 cells were either in exponential growth or grown to
confluency (plateau or stationary phase), then the culture
medium was renewed daily for 3 days and experiments were
performed on the following day. Stationary or plateau phase
was determined by maintaining parallel dishes of cells which
were counted daily until a constant number of cells were
reached. Cultures were then prepared for use in the experi-
ments. After exposure to the drug or vehicle for I h, the cells
were washed three times with 0.9% phosphate-buffered
saline (PBS) and suspended by treatment with 0.25% trypsin.
The cells were plated in duplicate dishes at three dilutions
for colony formation. After 2 weeks, the colonies were
visualised by staining with crystal violet and colonies of 50
cells or greater were counted. The results were expressed as
surviving fraction of treated cells compared to vehicle-treated
control cells (Teicher et al., 1985).
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Figure 1 Structures of the platinum-dye complexes.
Survival studies for PLDR
Stationary phase cultures of SCC-25 cells were prepared as
described above. The cells were exposed to 100 Mgml - of
bleomycin for 1 h at 37°C in fresh serum-free medium. The
medium covering the monolayers before treatment (depleted
medium) was retained and used to cover the cultures during
the delay from subculture period. After treatment with
bleomycin, the dishes were rinsed twice with PBS and
depleted medium was added. Platinum complexes were
added to the depleted medium for the duration of the delay
to the time of subculture. The concentrations of platinum
complexes were 0.5iM Pt(Rh-123)2, 5MM Pt(fast black)2,
0.5 gM Pt(pyronin Y)2, 5MM Pt(thioflavin)2, 5,M Pt(thio-
nin)2 and 5 pM Pt(methylene blue)2. Similar dishes which
had not been treated with bleomycin were exposed to the
platinum complexes for the same time periods to assess the
cytotoxicity of the platinum complexes alone. Other dishes
were exposed to bleomycin and each of the platinum com-
plexes simultaneously for 1 h then immediately subcultured.
Both treated and control dishes were held for 0, 1, 2, 4, 6
and 24h at 37°C; cells were then washed twice with PBS,
suspended by trypsinisation and counted by haemocyt-
ometer. Comparison experimental control plates showed no
significant cell loss through lysis. Known numbers of cells
were plated in duplicate dishes at three dilutions for colony
formation as described above (Holden et al., 1987).
Data analysis
Quantitative analysis of survival curves was performed using
the log-probit iterative least squares method of Litchfield &
Wilcoxon (1949) as revised by Tallarida & Murray (1981).
Calculations were performed on an Apple II+ micro-
computer. Recovery ratios (R/Ro) were calculated by divid-
ing the surviving fraction immediately after drug exposure
(RO) into the surviving fraction of cells at each time post-
treatment (R), corrected for the cytotoxicity of the inhibitor.
A recovery ratio of 1.0 means no recovery or repair of
damage, and a ratio of greater than 1.0 means recovery from
PLD (Barranco & Townsend, 1986).
Results
The structures of the platinum-dye complexes are shown in
Figure 1. The other dye complexes are analogues to Pt(Rh-
123)2 with two dye molecules associated in a tight ion pair
with the platinum tetrachlorodianion. The SCC-25 cell line is
a well-established line derived from a human squamous
carcinoma of the head and neck (Teicher et al., 1987). When
in exponential growth, 1 log of SCC-25 cells were killed by
22Mm of CDDP with a 1 h exposure time. With stationary
SCC-25 cells, 1 log of cell kill was obtained with 40Mm of
CDDP in a 1 h exposure time. All of the platinum-dye
complexes studied were more toxic towards exponentially
growing SCC-25 cells than towards SCC-25 cells exposed to
the drugs for 1 h while in stationary phase (Figure 2). The
survival curves for SCC-25 cells exposed to Pt(Rh-123)2 in
exponential growth or in stationary phase are both biphasic.
At 250giM of Pt(Rh-123)2, on the terminal slopes of both
curves, there is a 20-fold difference in cell killing with the
stationary phase cell being less sensitive to the drug. With
the platinum-dye complex Pt(fast black)2, there is an even
greater difference between the cytotoxicity of the drug to
cells in exponential phase compared to stationary phase,
which increased with increasing drug concentration reaching
2.5 logs at a concentration of 250pM of Pt(fast black)2.
Pt(pyronin Y)2 was a more potent cytotoxic agent than
Pt(Rh-123)2 or Pt(fast black)2. With Pt(pyronin Y)2 there
was more than 2 logs greater killing of exponentially grow-
ing SCC-25 cells than stationary phase SCC-25 cells at a
drug concentration of 50MM.
Pt(thioflavin)2 was the most cytotoxic of the platinum-dye
complexes examined. Pt(thioflavin)2 was also more cytotoxic
towards exponentially growing SCC-25 cells than toward
stationary phase SCC-25 cells, but the differential was
smaller (1 log at 10Mm) than with the other agents tested.
Pt(thionin)2 was similar in cytotoxicity to Pt(fast black)2. At
250Mm of Pt(thionin)2 there was about 2 logs greater kill of
exponentially growing SCC-25 cells than of stationary phase
SCC-25 cells. The survival curve of stationary phase SCC-25
cells exposed to Pt(methylene blue)2 was biphasic whereas
that of the exponentially growing cells was linear over the
dosage range examined. There was about a 30-fold greater
kill of exponentially growing SCC-25 cells with Pt(methylene
blue)2 than of stationary phase SCC-25 cells at 1OOMm drug
concentration.
Figure 3 shows the survival curve for stationary phase
SCC-25 cells exposed to various concentrations of bleo-
mycin. The survival curve is biphasic with an initial sensitive
phase and a less sensitive second phase, as is common for
many cell lines (Twentyman, 1984). After stationary phase
SCC-25 cells were exposed to 100pgml-1 of bleomycin for
1 h, the drug was removed and the cells were allowed various
periods for PLD recovery. The capacity of the SCC-25 cell
line for PLDR following X-ray treatment has been docu-
mented with a 24 h recovery ratio (R/Ro) of 6.2
(Weichselbaum, 1982). After 24h, the SCC-25 cells showed a
recovery ratio (R/Ro) of 11.0 which corresponded to an
immediate survival at a drug level of 9Mgml-1, a dose 11-
fold less than the exposure concentration of 100Mgml-1.
The recovery ratio for SCC-25 cells following bleomycin
treatment increased rapidly at early time points: 4.3 at 1 h,
6.7 at 2h and 8.7 at 4h. The rate of recovery slowed after
4h so that the recovery ratio was 9.8 at 6h and 11.0 at 24h.
Over the course of the first 6h of PLD recovery, 0.5 uM
CDDP was an effective inhibitor of PLDR (Figure 3). The
concentration of 0.5gM of CDDP was selected for these724 Y. WANG et al.
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Figure 2 Survival of exponentially growing (0) and stationary phase (0) SCC-25 cells exposed to various concentrations of each
platinum-dye complex for 1 h. Points are means of three independent experiments and bars are s.e.m.
studies because this concentration of CDDP was essentially
non-toxic over the 6h holding period. Simultaneous treat-
ment of the cells with bleomycin and 0.5Mm CDDP for 1 h
with immediate subculture resulted in cell kill equal to that
of bleomycin alone. For the first hour, while R/Ro was 4.3
for bleomycin alone, with 0.5UM CDDP the R/Ro was 1.2.
Between 2 and 4h the R/Ro was 1.9-2.7 in the presence of
CDDP and 6.7-8.7 without CDDP. The inhibitory effect of
CDDP was still evident at the 6h point since in the presence
of CDDP the recovery ratio was 3.7 compared to 9.8
without CDDP. By 24h post-treatment, however, the
recovery ratio was 8.0, more closely approaching the 11-fold
recovery observed in the absence of CDDP. This continued
low level of recovery probably reflects the presence of a
small concentration of bleomycin remaining inside of the
cells, which at 24h was still active.
The capability of essentially non-toxic concentrations of
the six platinum-dye complexes to inhibit PLD recovery of
stationary phase SCC-25 cells after exposure to bleomycin
was assessed (Figure 4). Simultaneous exposure of stationary
phase SCC-25 cells to bleomycin (100ugml-1) and each of
the platinum-dye complexes for 1 h followed by immediate
subculture resulted in cell kill equal to that of bleomycin
alone for 1h. Pt(Rh-123)2 at a concentration of 5gM was
not a very effective inhibitor of bleomycin PLD repair. Over
the 6h recovery time period (Figure 4a), there was less than
a 1.5-fold difference between the PLDR observed in the
presence or absence of Pt(Rh-123)2. Pt(fast black)2 at SliM,
however, proved the most effective inhibitor of bleomycin
PLDR. After exposure to Pt(fast black)2 the 1 h post-
bleomycin exposure recovery ratio was 1.1, by 2h the
recovery ratio increased to 2.3 and continued to increase
slowly to 2.5 and to 2.7 at 4 and 6h, respectively. Thus
Pt(fast black)2 (5pM) was a more effective inhibitor of
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Figure 3 Survival curve for stationary phase SCC-25 cells
treated with various concentrations of bleomycin for 1 h (0).
Inset: PLD recovery (0) showing the loss of effectiveness of
bleomycin (100 gml-1) due to recovery from potentially lethal
damage over 24h and reduced PLD recovery (El) from the same
bleomycin treatment in the presence of 0.5/M CDDP. Points are
means of three independent experiments and bars are s.e.m.
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Figure 4 a, b and c, Survival of stationary phase SCC-25 cells treated with 100jigml 1 bleomycin which were allowed various
periods of time for PLD recovery (*). a, Survival of these same cells exposed to 5Mm Pt(Rh-123)2 (@) or 5pM Pt(fast black)2 (U)
during the PLD recovery period. Survival of untreated cells exposed to 5Mm Pt(Rh-123)2 (0), or 5Mm Pt(fast black)2 (El) for the
indicated time periods. b, Survival of these same cells exposed to O.5 Mm Pt(pyronin Y)2 (0) or O.5,M Pt(thioflavin)2 (U) during
the PLD recovery period. Survival of untreated cells exposed to O.5Mm Pt(pyronin Y)2 (0) or O.5M Pt(thioflavin)2 (EC) for the
indicated time periods. c, Survival of these same cells exposed to 5MM Pt(methylene blue)2 (0), or 5Mm Pt(thionin)2 (U) during
the PLD recovery period. Survival of untreated cells exposed to 5MM Pt(methylene blue)2 (0) or 5,UM Pt(thionin)2 (C]) for the
indicated time periods. Points are means of three independent experiments and bars are s.e.m.
bleomycin PLD recovery than was CDDP (0.5gM) in this
system.
Pt(pyronin Y)2 at a concentration of 0.5gM was a moder-
ately effective inhibitor of bleomycin PLD repair (Figure
4b). After 1 h of repair time, the recovery ratio was 3.1 in
the presence of Pt(pyronin Y)2 compared to 4.3 in the
absence of the drug. Throughout the remaining recovery
period tested from 2 to 6h, the recovery ratio was 2-fold
lower in the presence of 0.5gM of Pt(pyronin Y)2 than in the
absence of the drug. At this same drug concentration
(0.5 Mm), Pt(thioflavin)2, was able to inhibit repair of bleo-
mycin damage in the SCC-25 cells effectively. In the recovery
period from 2 to 6h, there was about 3.5-fold less recovery
of survival in SCC-25 cells in the presence of the drug than
in the absence of the drug. The recovery ratios in the
presence of 0.5pM Pt(thioflavin)2 were 1.9, 2.2 and 3.0 at 2,
4 and 6h compared with 6.7, 8.7 and 9.8 at these same time
points in the absence of the repair inhibitor.
The ability of Pt(methylene blue)2 at a concentration of
5pM to inhibit the repair of bleomycin damage is shown in
Figure 4c. Pt(methylene blue)2 was only moderately effective
as a PLD repair inhibitor with decreasing effectiveness at
longer recovery times. The recovery ratio in the presence of
5pM Pt(methylene blue)2 at 1 h was 2.3 and at 6h was 7.0 as
compared with recovery ratios of 4.3 at 1 h and 9.8 at 6h in
the absence of drug. Therefore, after 1 h of recovery time
there was a 1.9-fold difference between recovery in the
presence and absence of the drug and after 6h of recovery
time there was a 1.4-fold difference in the presence and
absence of the drug. Pt(thionin)2 in a concentration of 5pM
is an effective inhibitor of bleomycin PLD repair in station-
ary phase SCC-25 cells, giving recovery ratios of 1.0, 1.8, 2.8
and 3.7 at recovery times of 1, 2, 4 and 6h, respectively.
Therefore, Pt(thionin)2 at a concentration of 5 pM was a
more effective PLDR inhibitor than 0.5O M CDDP at short
recovery times and was comparable in effectiveness to 0.5gM
CDDP at longer recovery times.
Discussion
The clinical significance of PLDR, defined here as recovery
of survival before subculture, has remained controversial
(Twentyman, 1984; Weichselbaum et al., 1982, 1984) but it
seems reasonable that drug combinations which inhibit the
ability of tumour cells to repair significant portions of drug-
induced damage will lead to improved clinical efficacy. The
ability of mammalian cells to recover from bleomycin-
induced damage has been well-documented both in vitro and
in vivo (Barranco & Townsend, 1986). This process can be
inhibited with actinomycin D, ethanol and hyperthermia
(Barranco, 1978; Twentyman, 1984) or under hypoxic con-
ditions by misonidazole (Korbelik et al., 1985). More
recently it has been shown that some platinum complexes
can inhibit the recovery of V79 cells from radiation-induced
cell kill (O'Hara et al., 1986). We have shown that, like
CDDP, six other novel platinum complexes can inhibit, to
various degrees, PLD recovery of stationary phase SCC-25
cells treated with bleomycin and increased repair is one
possible mechanism of resistance to chemotherapeutic agents
(Teicher et al., 1986).
These platinum-dye complexes were prepared in an effort
to develop platinum-containing drugs which would have
greater tumour selectivity than platinum-containing anti-
cancer agents that are currently in clinical use. The inter-
action of several of these drugs with hyperthermia and
radiation has been described in vitro (Herman & Teicher,
1988; Herman et al., 1988; Teicher & Herman, 1988;
Teicher & Holden, 1987; Teicher et al., 1986). Inhibition of
repair can also be an important component of drug action.726 Y. WANG et al.
In this study, Pt(fast black)2 (5pM) was the most effective
new complex as an inhibitor of PLD recovery after bleomy-
cin exposure. Over a 6 h period, Pt(fast black)2, Pt(thiofla-
vin)2 (0.5gM) and Pt(thionin)2 (5gM) were at least as
effective at inhibiting recovery after treatment with bleomy-
cin as was CDDP. Pt(Rh-123)2 (5/uM) Pt(pyronin Y)2
(0.5 pM) and Pt(methylene blue)2 (5pM) were less effective
inhibitors of bleomycin PLD recovery in this cell line. These
studies demonstrate that to differing degrees, non-toxic
concentrations of these new platinum-dye complexes can
prevent or postpone the recovery of survival of stationary
phase SCC-25 cells exposed to bleomycin. Further experi-
ments will be needed to define the mechanism(s) of this
phenomenon whether it is interaction with a repair mecha-
nism, interaction between bleomycin and the platinum-
containing drugs or between the platinum-containing drugs
and DNA. Experiments are in progress exploring the mecha-
nism of PLDR inhibition by these agents and the efficacy of
these new platinum-containing drugs as inhibitors of radia-
tion PLDR in vitro and as cytotoxic agents alone and in
combinations with radiation, hyperthermia and other che-
motherapeutic drugs in vivo.
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